Improving Outcomes in Diabetes: Focus on SGLT2 Inhibitors. A Medical Experts Discussion
Published: 01 April 2021
-
Views:
4898
-
Likes:
7
-
Views:
4898
-
Likes:
7
-
Up Next
-
12m 33sPart 4 Su Down
-
11m 33sPart 5 Jas Gill
-
2m 30sPart 1 Jas Gill, Andrew Frankel, Derek Connolly, Su Down Jas Gill, Andrew Frankel, Derek Connolly, Su Down
-
13m 27sPart 2 Andrew Frankel Andrew Frankel
Overview
This programme has been created with a view to educate primary care healthcare professionals in the UK to understand when, and for whom, they should prescribe SGLT2 inhibitors and to understand the latest advancements in this drug class.
Boehringer Ingelheim Ltd has supported this event as a Medical Education Grant and has had no other involvement in the organisation or the delivery of this programme.
Key Learning Objectives
- Describe how and when to prescribe SGLT2 inhibitors
- Identify patients who are suitable for SGLT2 inhibitors
- Provide appropriate patient education and advice when initiating SGLT2 inhibitors
- Recall the patient populations in whom SGLT2 inhibitors have proven efficacy and safety
Faculty
- Dr Jas Gill - GP with Special Interest in Cardiology
- Dr Andrew Frankel - Consultant Nephrologist
- Dr Derek Connolly - Consultant Interventional Cardiologist
- Su Down - Nurse Consultant in Diabetes
More from this programme
Part 1
Welcome and Introductions
Part 2
SGLT2 inhibitors: Initiation in Diabetic Kidney Disease
| 1 session | |
| Andrew Frankel | Watch now |
Part 3
SGLT2 Inhibitors in Heart Failure
| 1 session | |
| Derek Connolly | Watch now |
Faculty Biographies
Derek Connolly
Consultant Interventional Cardiologist
Professor Derek Connolly is a Consultant Interventional Cardiologist and the Director of Research and Development at Birmingham City Hospital. He is an Honorary Senior Clinical Lecturer at the Institute of Cardiovascular Sciences, University of Birmingham, UK.
He trained in Cambridge, London, Edinburgh and San Diego where he was a Carnegie Scholar. He has a first-class degree in Pharmacology from the University of Edinburgh where he was the Brunton medallist and Keasbey Bursary holder. His PhD in molecular cardiology is from the University of Cambridge. He is the Chief or Primary Investigator of multiple large trials in Cardiovascular medicine. He developed one of the UK's first primary angioplasty programmes and one of the UK's largest cardiac CT programmes.